Synbiotic, Prebiotics and Probiotics in Children With Cerebral Palsy and Constipation

Efficacy of the Supplementation With a Symbiotic, a Prebiotic and a Probiotic to Produce a Beneficial Effect on the Intestinal Microbiota and on the Characteristics of Feces in Children With Cerebral Palsy (CP) and Chronic Constipation

Sponsors

Lead Sponsor: Andrea Garcia Contreras

Source Hospital Civil Juan I. Menchaca
Brief Summary

Randomized double blind controlled clinical trial. Participants will be enrolled at the New Civil Hospital of Guadalajara "Dr. Juan I. Menchaca" during the period from May 2017 to July 2018, from six to 59 months of either sex. The duration of each participant in the study will be of four weeks. Each participant will be randomized assigned to any of the different study groups: synbiotic, prebiotic, probiotic or placebo. Hypothesis: The efficacy of supplementation with a symbiotic, a prebiotic and a probiotic differs in its beneficial effect on the intestinal microbiota and the characteristics of feces in children with CP and chronic constipation.

Detailed Description

All the data registered in the case report forms will be monitored by the responsible party. This person will be monitoring each procedure during the study. All the data in the case report forms will be obtained from the information obtained from the legal caregiver or the parents of the child and/or from the medical and electronic records and calls to the parents or legal caregivers and will be introduced daily in the Statistical Package for the Social Scienses (SPSS) program version 21. The responsible party will have access to this database and will verify the information. Plan for missing data. In case that we have some missing variables, we will call the parents or legal caregiver of the children if it is about the data of the child. In case of missing data, unavailable or non-reported variable and it is not possible to compare the initial vs final phases, the subject will be excluded from the study. In case of finding an out-of-range laboratory results we will repeat the test. If we have some missing data from the subject but we can analyze other results from the same subject, it will not be excluded. Standard Operating Procedures to address registry operations and analysis activities, such as patient recruitment, data collection, data management, data analysis, reporting for adverse events, and change management. Patients will be recruited from the nutrition and neurology outpatient at the New Hospital Civil of Guadalajara. We will apply a standardized questionnaire to the parents or legal caregivers to assure that the subject could be eligible to the study. Once all the inclusion criteria are fulfilled then another questionnaire or case report form will be filled. The informed consent will be explained and given to the parents or legal caregivers of the child for sign. An external person will be chose to assign randomly (by envelops) the subjects to each group. This person will provide the study product and the diaries to the parents or legal caregivers. Data from the case reports forms will be captured by the principal investigator and monitored by the responsible party. Te adverse events will be reported by phone calls during the four weeks (two to three phone calls in a week). To analyze the information, the SPSS program version 21 will be used. Sample size. The sample size was calculated according to the next formula: n= K (σ12 + σ22)/ (μ1 - μ2) 2 = 6.2 (1.12 + 0.62)/ (4.01 - 2.8) n= 7 + 3 (30% probability of exclusion) = 10 children for each group, total subjects in the study: 40. α= 0.05 β= 0.20 Data was obtained from the study of Indrio F, et al (2014) 18 with the number of evacuation. Sampling system. Simple random sample by means of closed envelopes with a figure inside. We will have 40 envelopes closed, 10 of them will have a circle, 10 a triangle, 10 a star and 10 a heart. They will be put into a box; this will be rotated five times before taking an envelope. Randomly, a person outside the study will take an envelope, will see the chosen figure and will write it down in the register. Statistical analysis. First stage. Shapiro Wilk test will be performed to see the distribution of the data. Descriptive statistics: mean, standard deviation, percentages and frequencies will be performed. Second stage. Analytical statistics: Intra-groups: Student's T test for dependent samples for parametric data or the Wilcoxon test for non-parametric data. Chi square for analysis of qualitative data. Inter-groups: One-way ANOVA with post hoc (Bonferroni) tests. If the data are not parametric, Kruskal-Wallis and if it is significant, Mann Whitney's U will be performed as post hoc. Third stage. Linear regression and logistic regression will be performed. Ethical considerations. Parents or legal representatives of the child will be informed about the study, requesting their signature for consent. Human research guidelines will be respected according to "good clinical practice". The protocol will be submitted to the Bioethics Committee of the New Civil Hospital of Guadalajara and the University of Guadalajara. Care will be taken to respect the recommendations of the Helsinki Declaration in its last correction made during the 64th Annual Assembly organized by the World Medical Association (2013).

Overall Status Completed
Start Date 2017-06-05
Completion Date 2018-12-21
Primary Completion Date 2018-12-21
Phase Phase 4
Study Type Interventional
Primary Outcome
Measure Time Frame
Change in the composition of the microbiota (firmicutes, bifidobacteria and lactobacilli) change from baseline bacteria composition at four weeks
change in consistency of feces change from baseline consistency at four weeks
change in potential of hydrogen (pH) of feces Change from baseline pH at four weeks
change in frequency of evacuations change from baseline frequency at four weeks
Secondary Outcome
Measure Time Frame
change in the concentration of short chain fatty acids in feces Change from baseline concentration at four weeks
Enrollment 40
Condition
Intervention

Intervention Type: Biological

Intervention Name: agave inulin

Description: Duration: four weeks Dosage: powder 4 g/d

Intervention Type: Biological

Intervention Name: Lactobacillus reuteri DSM 17938

Description: Duration: four weeks Dosage: 5 drops/d

Intervention Type: Other

Intervention Name: maltodextrin

Description: Duration: four weeks Dosage: powder 4 g/d

Intervention Type: Other

Intervention Name: Oil mix (medium chain triglycerides and sunflower oil)

Description: Duration: four weeks Dosage: 5 drops/d

Eligibility

Criteria:

Inclusion Criteria: - Participants attending the outpatient of nutrition and/or pediatric neurology with cerebral palsy diagnosed and confirmed by a pediatric neurologist, and that belong to levels IV or V of the Gross Motor Function Classification System (GMFCS). - Participants with constipation according to the Rome IV criteria. - Signed informed consent by one of the child's parents or legal guardians Exclusion Criteria: - Refusal to continue in the study - Use of antibiotics during the study, consumption of laxatives, food fibers, lactulose, magnesia or products containing probiotics, prebiotics or both as infant formulas (NOTE: Glycerin suppositories will only be allowed when there is no evacuation for more than five days). - Omission of administration of the required dose of symbiotic, prebiotic, probiotic or placebo and/or administered with an unspecified frequency (compliance <95%) - Adverse effects not related to the agent of study.

Gender:

All

Minimum Age:

6 Months

Maximum Age:

60 Months

Healthy Volunteers:

No

Overall Official
Last Name Role Affiliation
Edgar M Vásquez-Garibay, Doctor Principal Investigator full time staff member at the Division of Pediatrics of the New Civil Hospital of Guadalajara
Location
Facility: Nuevo Hospital Civil de Guadalajara
Location Countries

Mexico

Verification Date

2018-04-01

Responsible Party

Type: Sponsor-Investigator

Investigator Affiliation: Hospital Civil Juan I. Menchaca

Investigator Full Name: Andrea Garcia Contreras

Investigator Title: Principal investigator

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 4
Arm Group

Label: Synbiotic

Type: Experimental

Description: Each participant will receive the next: agave inulin (4 g) in powder Lactobacillus reuteri DSM 17938 (1 x 10^8 cfu) in 5 drops daily, once a day for four weeks.

Label: Probiotic

Type: Experimental

Description: Lactobacillus reuteri DSM 17938 (1 x 10^8 cfu) in 5 drops and maltodextrin (4 g) in powder daily, once a day for four weeks.

Label: Prebiotic

Type: Experimental

Description: agave inulin (4 g) in powder and an oil mix (sunflower oil and medium chain triglyceride oil) in 5 drops daily, once a day for four weeks.

Label: Placebo

Type: Placebo Comparator

Description: maltodextrin (4 g) in powder and an oil mix (sunflower oil and medium chain triglyceride oil) in 5 drops daily, once a day for four weeks.

Patient Data No
Study Design Info

Allocation: Randomized

Intervention Model: Factorial Assignment

Intervention Model Description: Three interventions in parallel against a control group

Primary Purpose: Treatment

Masking: Triple (Participant, Care Provider, Investigator)

Masking Description: pediatric neurologist and laboratory staff.

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News